AMEND SURGICAL, INC.
ALACHUA, FLORIDA

Robby Lane co-founded Amend Surgical in June 2015 and currently serves as Chief Executive Officer of this medical device and biologics company located in Gainesville, FL. Before starting this current venture, Mr. Lane worked at RTI Surgical as Executive Vice President of Commercial Distribution where he had global responsibility of this $126 million division. Following RTI’s acquisition of Tutogen in 2008, Mr. Lane was appointed President and Managing Director at Tutogen Medical, GmbH in Neunkirchen, Germany. Mr. Lane began his career at RTI in 2006 as Vice President of Orthopedics and Spine. Prior to RTI, Mr. Lane worked as Vice President of Sales and Marketing at DeRoyal and before that served as Business Manager for the Hip Division at Stryker Corporation. A native of Knoxville, Tennessee, Mr. Lane earned a bachelor’s degree in Zoology from the University of Tennessee. He also earned a master’s degree in business administration from the University of Tennessee. Ronald Cobb has worked for over 20 years in the pharmaceutical and medical device fields. While he was Director of Research at RTI Biologics, more than 20 new products and line extensions were launched. Ron is currently Chief Scientific Officer at Nanotherapuetics, Inc., focusing on the R&D and Manufacturing of various vaccine and recombinant protein pharmaceutics. Amend Surgical is focused on enhancing the healing and regenerative capacity of bone grafts. We are manufacturing and developing a product portfolio of natural and synthetic bone graft substitutes. Amend Surgical is committed to innovation and advancing the science of orthobiologics. The power of bioactive glass and the consistency of demineralized allograft bone in a single product. NanoFUSE® Bioactive Matrix is a novel bone graft substitute expressly designed to optimize surgical handling, graft stability and osteoproductivity in orthopedic and spine surgery. NanoFUSE® Bioactive Matrix incorporates human demineralized bone matrix (DBM) and synthetic calcium phosphor-silicate particulate material particles (45s5 bioactive glass), both coated with gelatin. Offered in multiple forms the active components are combined with a natural carrier to encapsulate the bioglass and demineralized bone while not interfering with the clinical usefulness of the product. The novel and patented coating process produces a product that is easy to prepare with optimal handling characteristics. Co-Founder and Chief Executive Officer, Robby Lane, has worked for over 25 years in the medical device and biologics fields. He was President and Managing Director at Tutogen Medical in Neunkirchen, Germany where he led the financial and global market expansion of this division of RTI Surgical. Most recently, he worked as Executive Vice President of Commercial Distribution at RTI Surgical where he drove product development and the exponential expansion of the company’s commercial partnerships. Co-Founder Ronald R. Cobb, Ph.D., has worked for over 20 years in the pharmaceutical and medical device fields. While he was Director of Research at RTI Biologics, over 20 new products and line extensions were launched. Ron is currently Chief Scientific Officer at Nanotherapeutics, Inc., focusing on the R&D and Manufacturing of various vaccine and recombinant protein pharmaceutics. Product Research Amend Surgical has optimized multiple proprietary processes to include extraction and attachment of a wide range